Publications 2023

Boye K, Gorunova L, Gunawan B, Hompland I, Sander B, Panagopoulos I, Langer C, Golas M, Heim S, Füzesi L, Hølmebakk T, Micci F (2023)
Genomic Complexity as a Biomarker to De-Escalate Adjuvant Imatinib Treatment in High-Risk Gastrointestinal Stromal Tumor
JCO Precis Oncol, 7, e2200351
DOI 10.1200/PO.22.00351, PubMed 36724411

Lloret I, Hompland I, Lobmaier IV, Sundseth J, Server A (2023)
Ewing sarcoma of the temporal bone with aneurysmal bone cyst-like changes: A rare case report with an unusual radiological presentation
Neuroradiol J, 19714009231212358 (in press)
DOI 10.1177/19714009231212358, PubMed 37923348

Publications 2022

Boye K, Lobmaier I, Kobbeltvedt MR, Thorkildsen J, Taksdal I, Bjerkehagen B, Bruland ØS, Zaikova O, Sundby Hall K, Hompland I (2022)
Real-world evidence on perioperative chemotherapy in localized soft tissue sarcoma of the extremities and trunk wall; a population-based study
Acta Oncol, 61 (7), 793-800
DOI 10.1080/0284186X.2022.2082259, PubMed 35698755

Fauske L, Wærstad PH, Hompland I, Bruland ØS (2022)
Hope as a Lifeline: Imatinib Discontinuation in Patients With Oligometastatic Gastrointestinal Stromal Tumours
Anticancer Res, 42 (2), 955-963
DOI 10.21873/anticanres.15555, PubMed 35093895

Gorunova L, Boye K, Panagopoulos I, Berner JM, Bjerkehagen B, Hompland I, Lobmaier I, Hølmebakk T, Hveem TS, Heim S, Micci F (2022)
Cytogenetic and molecular analyses of 291 gastrointestinal stromal tumors: site-specific cytogenetic evolution as evidence of pathogenetic heterogeneity
Oncotarget, 13, 508-517
DOI 10.18632/oncotarget.28209, PubMed 35284037

Seidensaal K, Dostal M, Liermann J, Adeberg S, Weykamp F, Schmid MP, Freudlsperger C, Hoffmann J, Hompland I, Herfarth K, Debus J, Harrabi SB (2022)
Inoperable or incompletely resected craniofacial osteosarcoma treated by particle radiotherapy
Front Oncol, 12, 927399
DOI 10.3389/fonc.2022.927399, PubMed 36212490

Publications 2021

Boye K, Longhi A, Guren T, Lorenz S, Næss S, Pierini M, Taksdal I, Lobmaier I, Cesari M, Paioli A, Løndalen AM, Setola E, Hompland I, Meza-Zepeda LA, Sundby Hall K, Palmerini E (2021)
Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial
Cancer Immunol Immunother, 70 (9), 2617-2624
DOI 10.1007/s00262-021-02876-w, PubMed 33580363

Hompland I, Ferrari S, Bielack S, Palmerini E, Hall KS, Picci P, Hecker-Nolting S, Donati DM, Blattmann C, Bjerkehagen B, Staals E, Kager L, Gambarotti M, Kühne T, Eriksson M, Ferraresi V, Kevric M, Biagini R, Baumhoer D, Brosjø O, Comandone A, Schwarz R, Bertulli R, Kessler T, Hansson L et al. (2021)
Outcome in dedifferentiated chondrosarcoma for patients treated with multimodal therapy: Results from the EUROpean Bone Over 40 Sarcoma Study
Eur J Cancer, 151, 150-158
DOI 10.1016/j.ejca.2021.04.017, PubMed 33990016

Hølmebakk T, Wiedswang AM, Meza-Zepeda LA, Hompland I, Lobmaier IVK, Berner JM, Stoldt S, Boye K (2021)
Integrating Anatomical, Molecular and Clinical Risk Factors in Gastrointestinal Stromal Tumor of the Stomach
Ann Surg Oncol, 28 (11), 6837-6845
DOI 10.1245/s10434-021-09605-8, PubMed 33651216

Våde L, Hompland I, Fauske L (2021)
Exploring Mentorship as a Novel Approach to Improving Quality of Life in Sarcoma Survivors: A Qualitative Pilot Study
Sarcoma, 2021, 2042785
DOI 10.1155/2021/2042785, PubMed 34421328

Publications 2020

Fauske L, Hompland I, Lorem G, Hall KS, Bondevik H (2020)
Striving towards Normality in Daily Life: A Qualitative Study of Patients Living with Metastatic Gastrointestinal Stromal Tumour in Long-Term Clinical Remission
Sarcoma, 2020, 1814394
DOI 10.1155/2020/1814394, PubMed 33082706

Hamre CFB, Kvammen EMH, Vinge LE, Skeie AT, Hompland I (2020)
[Cardiac sarcoma]
Tidsskr Nor Laegeforen, 140 (6)
DOI 10.4045/tidsskr.19.0455, PubMed 32321220

Hamre CFB, Kvammen EMH, Vinge LE, Skeie AT, Hompland I (2020)
Sarcoma of the heart
Tidsskr. Nor. Laegeforen., 140 (6), 582-583

Hompland I, Fauske L, Lorem GF, Bruland ØS (2020)
Use of a simple form to facilitate communication on long-term consequences of treatment in sarcoma survivors
Clin Sarcoma Res, 10, 2
DOI 10.1186/s13569-019-0124-3, PubMed 31969978

Publications 2019

Fauske L, Hompland I, Lorem G, Bondevik H, Bruland ØS (2019)
Perspectives on treatment side effects in patients with metastatic gastrointestinal stromal tumour: a qualitative study
Clin Sarcoma Res, 9, 6
DOI 10.1186/s13569-019-0116-3, PubMed 31061697

Hølmebakk T, Bjerkehagen B, Lobmaier IVK, Hompland I, Stoldt S, Boye K (2019)
Is Peritoneal Tumor Penetration of Prognostic Importance in Gastrointestinal Stromal Tumors?
Ann Surg Oncol, 26 (13), 4730-4736
DOI 10.1245/s10434-019-07813-x, PubMed 31520212

Publications 2018

Boye K, Berner JM, Hompland I, Bruland ØS, Stoldt S, Sundby Hall K, Bjerkehagen B, Hølmebakk T (2018)
Genotype and risk of tumour rupture in gastrointestinal stromal tumour
Br J Surg, 105 (2), e169-e175
DOI 10.1002/bjs.10743, PubMed 29341147

Hompland I, Hølmebakk T, Boye K, Stoldt S, Bjerkehagen B, Berner JM, Wiedswang AM, Revheim ME, Poulsen JP, Hall KS, Bruland ØS (2018)
[Not Available]
Tidsskr Nor Laegeforen, 138 (15)
DOI 10.4045/tidsskr.18.0200, PubMed 30277049

Hølmebakk T, Bjerkehagen B, Hompland I, Stoldt S, Boye K (2018)
Relationship between R1 resection, tumour rupture and recurrence in resected gastrointestinal stromal tumour
Br J Surg, 106 (4), 419-426
DOI 10.1002/bjs.11027, PubMed 30507040

Hølmebakk T, Hompland I, Bjerkehagen B, Stoldt S, Bruland ØS, Hall KS, Boye K (2018)
Recurrence-Free Survival After Resection of Gastric Gastrointestinal Stromal Tumors Classified According to a Strict Definition of Tumor Rupture: A Population-Based Study
Ann Surg Oncol, 25 (5), 1133-1139
DOI 10.1245/s10434-018-6353-5, PubMed 29435684

Longhi A, Paioli A, Palmerini E, Cesari M, Abate ME, Setola E, Spinnato P, Donati D, Hompland I, Boye K (2018)
Pazopanib in relapsed osteosarcoma patients: report on 15 cases
Acta Oncol, 58 (1), 124-128
DOI 10.1080/0284186X.2018.1503714, PubMed 30207179

Publications 2017

Hompland I, Bruland ØS, Hølmebakk T, Poulsen JP, Stoldt S, Hall KS, Boye K (2017)
Prediction of long-term survival in patients with metastatic gastrointestinal stromal tumor: analysis of a large, single-institution cohort
Acta Oncol, 56 (10), 1317-1323
DOI 10.1080/0284186X.2017.1330555, PubMed 28557540

Publications 2016

Hompland I, Bruland ØS, Ubhayasekhera K, Bergquist J, Boye K (2016)
Clinical implications of repeated drug monitoring of imatinib in patients with metastatic gastrointestinal stromal tumour
Clin Sarcoma Res, 6, 21
DOI 10.1186/s13569-016-0062-2, PubMed 27999655

Publications 2015

Hompland I, Bruland ØS (2015)
Can Imatinib Be Safely Withdrawn in Patients with Surgically Resected Metastatic GIST?
Anticancer Res, 35 (11), 5759-65
PubMed 26503996

Hompland I, Rizvi SM, Winge M, Norum OJ, Bjerkehagen B, Ringen HO, Taksdal I, Mørk NJ, Hall KS (2015)
[A boy with a wound on his finger that would not heal]
Tidsskr Nor Laegeforen, 135 (5), 445-8
DOI 10.4045/tidsskr.14.0759, PubMed 25761032

Hompland I, Rizvi SMH, Winge M, Norum OJ, Bjerkehagen B, Ringen HO, Taksdal I, Mork NJ, Hall KS (2015)
A boy with a wound on his finger that would not heal
Tidsskr. Nor. Laegeforen., 135 (5), 444-447